A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)

2019135 citationsJournal Articlegold Open Access

Authors

Lu Si · Peking University

Xiaoshi Zhang · Sun Yat-sen University

Yongqian Shu · Jiangsu Province Hospital

Hongming Pan · Sir Run Run Shaw Hospital

Di Wu · First Hospital of Jilin University

Jiwei Liu · Dalian Medical University

Fang Lou ·

Abstract

Pembrolizumab was well tolerated and provided clinically meaningful antitumor activity as second-line therapy in Chinese patients with advanced melanoma.

Topics & Keywords

Cancer Immunotherapy and Biomarkers CAR-T cell therapy research Immunotherapy and Immune Responses

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Translational Oncology

Volume 12, Issue 6, pp. 828-835

DOI: 10.1016/j.tranon.2019.02.007

Field-Weighted Citation Impact: 7.48